Answers are grounded in this paper and cite their sources.
Introduction: Physiological changes associated with hypoxia occur at high altitudes, where early prevention is essential for aviation safety. Conventional monitoring methods, such as pulse oximetry, measure systemic oxygen saturation but may not detect early or subclinical hypoxic stress. Hypoxia-inducible factor-1 alpha (HIF-1α), a transcription factor stabilised under low-oxygen conditions, represents a potential early molecular biomarker of hypoxia. Materials and Methods: This study aimed to develop and evaluate a rapid, non-invasive, lateral flow immunoassay (LFIA)–based hypoxia sensor test to detect salivary HIF-1α following simulated high-altitude exposure. A prospective cohort study was conducted involving 24 healthy participants: 12 assessed at sea level and 12 exposed to a simulated altitude of 10,000 feet in a hypobaric chamber. Oxygen saturation (SpO 2 ), heart rate and blood pressure were recorded pre- and post-exposure. Saliva samples were analysed using a paper-based sandwich-format LFIA with gold nanoparticle–antibody conjugates for colorimetric detection of HIF-1α. Results: There is a significant reduction in mean SpO₂ from 98.1% ±0.65% at sea level to 90.7% ±0.76% at 10,000 feet ( P < 0.001), which shows development of hypoxia. At sea level, the salivary HIF-1 was undetectable, whereas there are 100% positive results during post-exposure at 10,000 feet (p<0.001). No hypoxia symptoms were reported during the study. Conclusion: The hypoxia kits for HIF-1α show remarkable specific sensitivity and sensitivity, supporting their potential as rapid, portable point-of-care tools for early screening of hypoxia at high altitude. In the future, a larger sample size will be needed for validation.
No takes yet. Share an insight, caveat, or question.
Shaharuddin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: